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 2 
ABSTRACT 1 
Fatty acid synthase (FAS) is highly expressed in many kinds of human cancers, 2 
including colorectal cancer (CRC), and we have investigated the potential use of FAS 3 
inhibitors for chemoprevention of liver metastasis of CRC in mice. Expression of FAS 4 
was evaluated in murine CRC cell line Colon 26 and CMT 93. Cerulenin, a natural 5 
inhibitor of FAS induced apoptosis in these cell lines. The ability of cerulenin to prevent 6 
development of liver metastatic lesion of Colon 26 was evaluated. The numbers and 7 
sizes of liver metastatic CRC tumors are significantly reduced by treating mice with 8 
cerulenin. Cerulenin treatment is associated with reduced levels of phosphorylated Akt 9 
in Colon 26 cells, suggesting that inhibition of this signal transduction pathway might 10 
be involved in the chemo preventive activity of this compound. Based on studies in 11 
mouse models, inhibiting FAS would be an effective strategy in preventing and 12 
retarding growth of liver metastatic tumors of CRC that have high expression of this 13 
enzyme. 14 
15 
 3 
Introduction 1 
Colorectal cancer (CRC) is one of the most common cancers in the world with 2 
more than million new cases (1). The liver is the commonest site of distant metastasis in 3 
CRC, and approximately 50% of patients ultimately develop liver metastasis in the 4 
course of CRC. (1, 2) Despite recent advances, systemic chemotherapy for metastatic 5 
disease is considered palliative, and we rarely see long-term survivors treated only by 6 
chemotherapy. (1) Hepatic resection, the only curative treatment for liver metastasis of 7 
CRC, has become the standard treatment, but most cases of liver metastases are 8 
inoperable and approximately 50% of the patients treated with hepatectomy have a 9 
tumor recurrence in the liver. (3)  10 
Fatty acid synthase (FAS) is highly expressed in many human cancers including 11 
CRC ,(4-7) and previous studies have shown that cancer cell growth can be suppressed by 12 
inhibiting the activity of this enzyme with a natural antibiotic cerulenin, (8) orlistat which 13 
is a pancreatic lipase inhibitor developed for obesity treatment , (9) and C75, which is a 14 
stable synthetic small-molecule developed specifically for inhibiting FAS.(10) But there 15 
are no previous studies in which FAS inhibitors suppress liver metastasis of CRC. 16 
The aim of this study extends the investigation of the potential use of a FAS 17 
inhibitor for chemoprevention of liver metastasis of CRC in mice. In this study, we 18 
examined the effect of cerulenin on the murine CRC cell line, Colon 26 and CMT 93 19 
cell proliferation and apoptosis. Then, the effect of cerulenin on the prevention of 20 
growth of liver metastasis lesion of Colon 26 was investigated.  21 
22 
 4 
Materials and Methods 1 
Cerulenin 2 
Cerulenin was obtained from Sigma(St. Louis, MO). For cell culture and i.p. 3 
injections, cerulenin was dissolved in acetone at a concentration of 20 mg/ml and stored 4 
at -20°C. In vitro experiment, 50 to 200 µM of cerulenin was added to the medium and 5 
cell viability assay and Western blot experiments were performed 24 hours later. In vivo 6 
experiments, treatment with cerulenin at 30 mg/kg was given i.p. at day 1, 4, and 7 after 7 
tumor inoculation in cerulenin group.  8 
Cell culture 9 
Two murine CRC cell lines, Colon 26 and CMT 93, were used and tested for 10 
mycoplasm-free cell lines. All cancer cell lines were subdivided in multiple tubes for 11 
stock in liquid nitrogen immediately after possession. All cell lines were subjected to 12 
present experiment within 6 months of resuscitation. Stock cultures were grown in high 13 
glucose DMEM containing 10% FBS and 1% antibiotics. The cells were grown in 14 
growth medium at 37°C in a 95% air, 5% CO2-humidified incubator.  15 
Cell viability assay 16 
To measure the cytotoxicity of cerulenin against these cancer cells, 3×103 cells 17 
were plated per well onto 96-well plates. Following overnight culture, cerulenin were 18 
added at specified concentrations. After 24 hours of incubation, cell viability was 19 
measured by the mitochondrial activity in reducing  20 
2-(2-Methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 21 
monosodium salt (WST-8) to formazan using Cell Counting kit-8 (Dojindo Laboratories, 22 
Kumamoto, Japan). Cells were incubated with a reagent as per manufacturer’s 23 
instructions. Plates were read at A450 on a spectrometer. 24 
 5 
Cell Proliferation Assay 1 
To measure the cell proliferation activity of cerulenin against these cancer cells, 2 
3×103 cells were plated per well onto 96-well plates. Following overnight culture, 3 
cerulenin were added at specified concentrations. After 24 hours of incubation, cell 4 
proliferation was measured by BrdU assay kit (Roche Diagnostics GmbH, Penzberg, 5 
Germany). Cells were incubated with a reagent as per manufacturer’s instructions. 6 
Plates were read at A450 on a spectrometer. 7 
Apoptosis assay 8 
The In situ Cell Death Detection kit (Roche diagnostics Corp., Basel, 9 
Switzerland) was used for the demonstration of apoptotic cell death of cell culture and 10 
liver tissue. 3×104 /ml cells were plated per well onto Lab-Tek II Chamber Slide (Nalge 11 
Nunc International K. K., Tokyo, Japan) and paraffin-embedded liver samples were 12 
incubated with the terminal deoxynucleotidyl transferase-mediated dUTP nick end 13 
labeling (TUNEL) reaction mixture according to manufacture’s recommendations.  14 
Western blot analysis 15 
For Western blot analysis, total protein extracts of Colon 26 and CMT 93 were 16 
obtained 24 hours after cerulenin treatment, and separated by 10% SDS-PAGE and 17 
transferred to nitrocellulose membrane (Millipore, Bedford, MA). The following 18 
antibodies were used as primary antibodies; total Akt (9272), phosphoserine 473 Akt 19 
(9271), p mTOR, cleaved caspase 3, and GAPDH (2118) (Cell Signaling, Beverly, MA). 20 
Purified mouse anti fatty acid synthase antibody (610962) was purchased from BD 21 
Biosciences (San Jose, CA). Secondary goat anti rabbit antibody conjugated with 22 
horseradish peroxidase was purchased from Zymed Laboratories Inc. (San Francisco, 23 
CA). Immunoblots were analyzed by enhanced chemiluminescence.  24 
 6 
Animals 1 
Eight-week-old male BALB/c mice (Clea, Japan), weighing 24–28g were utilized. 2 
The mice were kept in a temperature-controlled room on a 12-hour light-dark cycle. 3 
They had free access to water and standard chow throughout the experiment. After an 4 
acclimation period of at least 7 days, the mice were separated into two groups as 5 
follows: control group, mice without any treatment (n=8); and cerulenin group, mice 6 
with cerulenin treatment (n=6). All animal experiments were carried out in a humane 7 
manner after receiving approval from the Institutional Animal Experiment Committee 8 
of the University of Tsukuba and in accordance with the Regulation for Animal 9 
Experiments in our university and Fundamental Guideline for Proper Conduct of 10 
Animal Experiment and Related Activities in Academic Research Institutions under the 11 
jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology. 12 
Liver metastasis 13 
Under ether anesthesia, laparotomy was performed with mid line incision, and 14 
hepatic ischemia was induced by clamping the portal triad (the hepatic artery, portal 15 
vein, and bile duct) with a microclip (Aesculap, Tuttlingen, Germany) for 1 min. After 16 
1min reperfusion of the liver, 1×105 cells of colon 26 cells were injected into the lower 17 
splenic pole with a 27-gauge needle. Nine days after inoculation, mice were sacrificed 18 
and livers were removed for examination.  19 
Histochemical examination 20 
To assess the liver metastatic area, left and middle lobes of liver were divided in 21 
5mm slice, fixed with 10% formaldehyde, and embedded in paraffin. Thin sections 22 
(4µm) were stained with hematoxylin-eosin, and the percentage of liver metastatic area 23 
of Colon 26 cells was calculated using image-processing software WinROOF (Mitani 24 
 7 
Co., Fukui, Japan).  1 
Serum parameter 2 
Blood was collected from the plexus of the retro-orbital vein of mice. Blood was 3 
centrifuged for 10 min at 4°C at 3500 rpm. Supernatants were collected and stored at 4 
-80°C until tested by a serum multiple biochemical analyzer (Fuji Drichem; Fuji Film 5 
Inc., Tokyo, Japan) for measuring triglyceride, cholesterol, and ALT levels.  6 
Statistical analysis 7 
All data are expressed as the mean ± standard deviation of samples. Unpaired 8 
t-test was used for the comparison between the two groups. Comparisons between 9 
various points were using one-way ANOVA. Significant data were examined by 10 
Bonferroni-Dunn multiple comparisons post hoc test. In all cases, a P value <0.05 was 11 
considered significant.  12 
 13 
Results 14 
Dose-dependent inhibition of proliferation of CRC cell lines by cerulenin 15 
We initially determined whether cerulenin treatment led to inhibit CRC cell 16 
proliferation. CRC cells were treated with various doses of cerulenin for 24 h, and cell 17 
viability was assayed using WST-8 assay (Figure 1A) and BrdU assay (Figure 1B). 18 
Figure 1 A and B showed that as the dose of cerulenin increased from 100-200 µM, cell 19 
growth inhibition increased in a dose-dependent fashion in CRC cell lines. 20 
Cerulenin-induced growth inhibition was found to be statistically significant (p<0.05) 21 
(one way ANOVA) in 100, 150, and 200 µM of cerulenin compared to 0 µM.  22 
Induction of apoptosis via activation of caspase-dependent pathway by cerulenin  23 
In subsequent experiments, we determined the mechanism of the observed 24 
 8 
suppressive effect of cerulenin by WST-8 assays. The overexpression of FAS has been 1 
observed to cooperate with survival pathways, including the PI3K/Akt pathway. These 2 
two cell lines expressed FAS and p-AKT constitutively, and treatment of CRC cells with 3 
cerulenin suppressed FAS expression, dephosphorylated constitutive activated Akt, and 4 
increased cleaved caspase-3 in both Colon 26 and CMT 93 cells (Fig. 2A). TUNEL 5 
staining of CRC cells revealed that cerulenin induced apoptosis both in Colon 26 and 6 
CMT 93 cells in 50 to 100 µM (Fig. 2B).  7 
Inhibition of general lipogenesis by cerulenin 8 
To investigate the physiological consequences of in vivo inhibition of FAS, we 9 
administered cerulenin (30mg/kg body weight every 3 days) to mice by i.p. injection. 10 
We observed slight weight loss following treatment with no significant difference in 11 
comparison to the control group (Fig. 3). Serum triglyceride was significantly decreased 12 
in the cerulenin group compared to the control group. This suggests general lipogenesis 13 
in the liver was reduced by cerulenin (Fig. 4).    14 
Inhibition of tumor growth of liver metastasis of CRC by cerulenin 15 
We evaluated the potential effectiveness of cerulenin for metastatic liver tumors 16 
of the CRC cell line. Figure 5A showed histological cross sections of livers removed 17 
from representative control group and cerulenin groups. Growth reduction of metastatic 18 
liver tumors was recognized in the cerulenin group. Figure 5B indicates tumor areas of 19 
the liver in both groups. Tumor growth was significantly reduced by cerulenin 20 
administration. Figure 5C showed TUNEL staining of liver sections of control group 21 
and cerulenin group. In cerulenin group, apoptotic tumor cells were observed in the 22 
metastatic liver tumor.         23 
 24 
 9 
Discussion 1 
The present study extends the investigation of the potential use of a FAS inhibitor 2 
for chemoprevention of liver metastasis of CRC in mice. In this study, we revealed the 3 
effect of cerulenin on the murine CRC cell line, Colon 26 and CMT 93, on growth 4 
inhibition by inducing apoptosis. Also, the effect of cerulenin on the prevention of 5 
growth of liver metastasis lesions of Colon 26 was revealed. This is the first study on 6 
inhibiting liver metastasis of CRC by administrating FAS inhibitor, cerulenin. Many 7 
kinds of human cancer cells have high activities of FAS and numerous studies have 8 
described the cytotoxic effects of FAS both in vitro and in vivo. (4) The role of increased 9 
FAS in cancer cells and the mechanisms of cell killing by inhibitors of FAS are still not 10 
fully understood. (11)  11 
The effect of an intermediate metabolite of fatty acid synthesis on cancer cells is 12 
likely mediated through cell signaling pathways.(12) For example, inhibiting FAS 13 
decreases phosphorylation of Akt in ovarian cancer cells and suppresses HER2 over 14 
expression in breast cancer cells. (12, 13) The mechanism by which FAS inhibitor 15 
decreases Akt activation is still unclear, but one mechanism that is advocated is that 16 
fatty acids synthesized by FAS are incorporated into membrane phospholipids, which 17 
are known modulators of Akt activation. (14, 15) FAS has a major role in the synthesis of 18 
phospholipids. (16) When FAS expression is decreased by the treatment of cerulenin, less 19 
fatty acid will be synthesized and less phospholipid will be available. One of the 20 
important phospholipid is PIP3. PIP3 binds to Akt and its activating kinase PDK-1 with 21 
high affinity, and the phosphorylation of Akt is dependent on PIP3. (17) In this study, a 22 
decrease of phospholipids may result in inhibition of Akt activity in Colon 26 and CMT 23 
93 cell lines after cerulenin administration. Recently, Liu X et al. reported that inhibition 24 
 10 
of PI3K/Akt by cerulenin induces apoptosis in breast cancer cell lines via release of 1 
cytochrome and activation of caspase. (18) In our study it was clarified that inhibition of 2 
PI3K/Akt by cerulenin induces apoptosis in CRC cell lines via activation of caspase.  3 
Colon 26 is chemically derived colon cancer from BALB/c mice. (19) It is highly 4 
metastatic and many researchers use this cell line for study of liver metastasis of CRC in 5 
mice. (20) From these reports we used colon 26 for this study. P53 expression of colon 26 6 
is not fully understood, but reacts to IFN alpha to increase p53, and induce apoptosis. 7 
(21) Functional p53 reacts to interferon alpha or beta. (22) That means p53 in colon 26 8 
would be functional. Further investigation of p53 in colon 26 should be required.   9 
Many efforts to treat xenograft cancers with cerulenin or its derivative of C75 were 10 
reported in ovary, (23) prostate, (24) mesothelioma, (25) breast cancer, (26) and CRC. (27, 28) 11 
But there is no study of treatment of liver metastasis of CRC using cerulenin. In this 12 
study we report that cerulenin inhibits liver metastasis of CRC in a mouse model. In the 13 
prior studies, the use of cerulenin or C75 has been hampered by transient but severe 14 
anorexia and weight loss. Therefore, this compound could also limit the use in the 15 
clinical setting. (29, 30) Loftus et al (29) reported that cerulenin treatment 60mg/kg daily for 16 
7days caused severe weight loss. Pizer ES et al (23) reported that cerulenin treatment 17 
80mg/kg/daily for 7 days caused severe weight loss. Uddin S et al (15) reported that C-75 18 
treatment 10mg/kg or 20mg/kg twice weekly did not cause severe weight loss. In our 19 
experiments we obtained adequate liver metastasis 9 days after tumor injection. We 20 
treated cerulenin 10mg/kg or 30mg/kg twice weekly (every 3 days). In our preliminary 21 
study cerulenin treatment of 10mg/kg had no effect (data not shown). By treating 22 
30mg/kg of cerulenin every 3 days, inhibition of liver metastasis was observed. At this 23 
amount, serum triglyceride was significantly decreased in cerulenin group. That means 24 
 11 
FAS was really inhibited in our animal model. But we could not observe significant 1 
weight loss in this group compared to control group. This result indicated the amount of 2 
cerulenin in our experiment was appropriate for prevention of side effects of FAS 3 
inhibitor. We could not promote complete remission of metastatic tumors by cerulenin 4 
at this dose and the appropriate dose of cerulenin or other FAS inhibitors needs to be 5 
studied. Also, the effect of FAS inhibitors to the chemically induced colon cancer 6 
should be evaluated.  7 
One of the reasons for anorexia brought on by cerulenin or C75 is fatty acid 8 
oxidation by activating carnitine O palmitoyltransferase 1. (30) In recent years, it was 9 
reported that C93, which inhibits FAS but has no significant effect on fatty acid 10 
oxidation, is effective for treatment of human lung cancer xenografts. As a result, C93 11 
does not cause anorexia or weight loss. (11) In near future analogues of FAS inhibitors 12 
such as C93 would represent promising new treatments for cancer, including liver 13 
metastasis of CRC.  14 
In conclusion, an FAS inhibitor of cerulenin inhibits CRC cell line survival in vitro 15 
and in vivo models with liver metastasis. FAS would be a new drug target for liver 16 
metastasis of CRC. 17 
 18 
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Figure Legends 1 
 2 
Figure 1 3 
A. Effect of cerulenin on the WST-8 assay of murine CRC cell lines. CRC cell lines 4 
were treated with 0 to 200 µM cerulenin for 24h. Left, Colon 26; right, CMT93. * 5 
p<0.01 compared to 0 µM cerulenin. The values indicate ratio compared to 0 µM 6 
cerulenin as 100%.   7 
B. Effect of cerulenin on the BrdU assay of murine CRC cell lines. CRC cell lines were 8 
treated with 0 to 200 µM cerulenin for 24h. Left, Colon 26; right, CMT93. * p<0.01 9 
compared to 0 µM cerulenin. The values indicate ratio compared to 0 µM cerulenin as 10 
100%. 11 
Figure 2 12 
A. Cerulenin treatment causes down regulation of FAS and dephosphorylation of 13 
constitutive phosphorylation of Akt in CRC cell lines. Colon 26 and CMT 93 cell lines 14 
were treated with 0, 50, and 100 µM cerulenin for 24h. After cell lysis, equal amounts 15 
of proteins were separated by SDS-PAGE, transferred to Immobilon membrane, and 16 
immunoblotted with antibodies against FAS, p-Akt, cleaved caspase-3, and GAPDH as 17 
indicated. 18 
B. Cerulenin treatment causes apoptosis in CRC cell lines. TUNEL staining of Colon 26 19 
and CMT 93 cell lines which were treated with 0, 50, and 100 µM cerulenin for 24h.    20 
 21 
Figure 3 22 
Weight of animals for cerulenin and control groups in the experiment. Columns, mean; 23 
 17 
bars, SD. White bar, control group; black bar, cerulenin group.  1 
 2 
Figure 4 3 
Serum triglyceride 9 days after tumor inoculation. Columns, mean; bars, SD. White bar, 4 
control group; black bar, cerulenin group. *p<0.05 vs control group, t-test.  5 
 6 
Figure 5 7 
Cerulenin inhibits tumor growth of liver metastasis of CRC cell line in mice.  8 
A. Histologic cross sections of livers of control group (left) and cerulenin group (right). 9 
Arrows, metastatic tumors. Original magnification ×100.  10 
B. Tumor area in the liver of all animals in the experiment. Columns, mean; bars, SD. 11 
White bar, control group; black bar, cerulenin group. *p<0.05 vs control group, t-test. 12 
C. TUNEL staining of tumor tissues. Arrows indicated apoptotic tumor cells in 13 
cerulenin group. Original magnification ×200. 14 
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